Clinical Trials
7 trialsNCT05055063 2026-06-01
A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT07609706 2026-05-27
A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment
GlaxoSmithKline
Phase 1 Not yet recruiting
NCT05556798 2026-02-24
A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT04398680 2025-12-04
DREAMM 13
GlaxoSmithKline
Phase 1 Withdrawn
NCT04091126 2025-11-28
DREAMM 9
GlaxoSmithKline
Phase 1 Active not recruiting
NCT05065047 2025-11-12
Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT03828292 2025-08-19
An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments
GlaxoSmithKline
Phase 1 Completed